Ublituximab (TG-1101), A Novel Glycoenginereed Anti-CD20 mAb, in Combination with Ibrutinib in Patients with CLL and MCL; Results of an Ongoing Phase II Trial.

Drug Category: Array
Conference Category: Array
Lead Author: Sharman J, O'Connor O, et. al.
Published Date: 13/06/2014
Download Link: /wp-content/uploads/2019/03/EHA2014-PosterP880.PDF
Download Text: Download
Popup Confirmation?:
site-sidebar-layout: default
ast-site-content-layout: default
site-content-style: default
site-sidebar-style: default
theme-transparent-header-meta: default
stick-header-meta: default
astra-migrate-meta-layouts: set
Scroll to Top